treating patients with poor-risk cytogenetics with venetoclax and hmas
Published 2 years ago • 182 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
2:04
the impact of cytogenetics on treatment decisions in aml
-
2:45
the addition of venetoclax to hmas for the treatment of cmml: a retrospective psm analysis
-
1:51
the safety and efficacy of retreatment with venetoclax plus rituximab in r/r cll
-
1:31
clinical outcomes are poor for cll patients treated with venetoclax post-btki exposure
-
1:11
treatment options for patients with cll after failure of covalent btk inhibitors and venetoclax
-
4:52
5 acist cvi nächste prozedur vorbereiten
-
2:30
real-world outcomes of venetoclax azacitidine versus intensive chemotherapy in newly diagnosed aml
-
2:43
tim wassenaar, md, hematologist
-
0:42
talquetamab treatment in patients with r/r myeloma with prior exposure to t-cell-directed therapies
-
1:40
oral combination of hmas venetoclax in unfit or elderly patients with aml
-
2:37
maintenance venetoclax and 5-azacytidine in patients with aml
-
1:12
hma in combination with venetoclax and magrolimab in the treatment of aml
-
0:39
selecting patients with scd for allosct
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
2:41
bcl2 family changes associated with venetoclax resistance in multiple myeloma
-
3:03
outcomes following venetoclax monotherapy in patients with r/r wm in the real-world setting
-
2:16
venetoclax-based salvage therapy in patients with r/r aml previously treated with targeted agents
-
1:59
the efficacy of venetoclax-based salvage therapy in patients with previously treated r/r aml
-
0:49
venice ii trial: health-related qol in patients with cll treated with venetoclax
-
0:54
factors to consider when treating aml patients with complex karyotype
-
3:59
treatment cessation using venetoclax-based therapy for older patients with aml
-
2:22
treating patients with cll who progress after btk inhibitor therapy